KINE-101C

KINE-101C is a synthetic peptide drug developed by Kine Sciences for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and potentially other immune-mediated diseases. It acts as a modulator of regulatory T lymphocytes (Tregs), aiming to suppress autoimmune responses by activating these specialized T cells. The mechanism involves modulation of both humoral and cell-mediated immunity, positioning it as a disease-modifying therapy rather than merely symptomatic treatment. The drug is currently in Phase 1 clinical development, with its primary indication being CIDP[1][2]. Kine Sciences specializes in ultra-small peptides derived from novel anti-inflammatory cytokines, which are designed to offer advantages such as favorable pharmacokinetics, low immunogenicity, reduced antigenicity, lower production costs, and potential for oral administration[3][5].